According to filings with the U.S. Securities and Exchange Commission, iVIEW Therapeutics is raising up to $15,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Bo Liang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About iVIEW Therapeutics
iVIEW Therapeutics Inc. is a clinical stage ophthalmology drug development company. Its lead compound iVIEW-1201 is starting global phase II human clinical trials in early 2019 for the treatment of viral conjunctivitis, which is an unmet medical need with no current FDA approved treatment. iVIEW was established by serial entrepreneurs and clinical physicians and funded by reputable VCs and strategic corporate investors. Headquartered in 5 Cedarbrook Drive, Cranbury, New Jersey, with over 11,000 sq. ft. laboratories and offices. China headquarter is located in Hengqin New District, Zhuhai City with a development/manufacturing base located in Wuhu City, Anhui Province.

To learn more about iVIEW Therapeutics, visit http://www.iviewtherapeutics.com/

Contact:
Bo Liang, Chief Executive Officer
609-773-8580
https://www.linkedin.com/in/boliang/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.